Acute Kidney InjuryROGARNCT07816640
Renal Oxygenation-Guided AKI Reduction Trial
A study testing INVOS 5100C regional oxygen saturation monitoring system, RrSO2-guided perioperative management and Usual perioperative management in people with Acute Kidney Injury and Hepatectomy, run by Chinese PLA General Hospital at 20 sites in China.
Trial summary
Acute kidney injury (AKI) is a common complication after major liver surgery. This study will evaluate whether intraoperative management guided by renal regional oxygen saturation (RrSO₂), measured using near-infrared spectroscopy, can reduce postoperative acute kidney injury in adults undergoing elective hepatectomy. Read more about this study
- Who is it for?
- Ages 45 years and older
- Conditions the study is for
- Acute Kidney Injury, Hepatectomy
- What is being tested?
- INVOS 5100C regional oxygen saturation monitoring system, RrSO2-guided perioperative management and Usual perioperative management
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,200 participants
- Where
- 20 sitesChina
- Study dates
- 20 Sep 2026to 30 Dec 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 45 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥45 years.
- Scheduled for elective open, laparoscopic, or robot-assisted hepatectomy.
- Planned general anesthesia with tracheal intubation and an expected surgical duration ≥2 hours.
- Stable preoperative serum creatinine available before randomization, with baseline estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m².
- Body mass index <30 kg/m² and bilateral renal cortex-to-skin distance ≤4 cm on ultrasound, allowing reliable bilateral renal NIRS monitoring and stable baseline RrSO₂ signals.
- American Society of Anesthesiologists physical status I-III.
- Ability to understand the study and provide written informed consent.
Who cannot join
- Pre-existing or unstable renal dysfunction, including eGFR <60 mL/min/1.73 m², AKI before randomization, unstable or progressively increasing serum creatinine, end-stage kidney disease, chronic dialysis, previous kidney transplantation, or other significant renal disease that may interfere with postoperative AKI assessment.
- Concomitant surgery expected to directly affect renal function assessment, including nephrectomy, kidney transplantation, or renal artery or vein reconstruction.
- Emergency or rescue surgery, or inability to provide valid informed consent before surgery.
- Inability to obtain reliable bilateral renal RrSO₂ monitoring because of excessive tissue depth, positioning, skin lesions, scars, infection, hematoma, severe edema, jaundice, or other technical or anatomical factors despite appropriate sensor repositioning and troubleshooting.
- Severe systemic disease or high perioperative risk, including severe cardiac or pulmonary dysfunction, recent major cardiovascular or cerebrovascular events, severe anemia, or any condition judged by the investigator to make participation unsafe.
- Participation in another interventional clinical trial that may affect perioperative management, AKI risk, or the primary outcome, or any other condition judged by the investigator to make participation unsuitable.
Trial locations and contacts
20 sites in 1 country. Contact the study team or a site near you to ask about taking part.
20 sites in 1 country
China20 sites
Chinese PLA General Hospital
Beijing, Beijing Municipality, 100853
Hao Li, 15010665099, lihao301@126.com
lihao301@126.com
Beijing Tsinghua Changgung Hospital
Beijing, Beijing Municipality
Huan Zhang, +86 13611326452, whta01956@btch.edu.cn
Hunan Provincial People's Hospital
Changsha, Hunan
Lai Wei, +86 13975856480, 448027999@qq.com
Xiangya Hospital of Central South University
Changsha, Hunan
E Wang, +86 18874889950, ewang324@csu.edu.cn
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality
Su Min, +86 13508302749, ms89011068@163.com
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong
Xiaoyun Lin, +86 13539498378
The Third Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong
Ziqing Hei, +86 13925020330, heiziqing@sina.com
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang
Foquan Luo, +86 13979197017, lfqjxmc@126.com
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang
Fei Han, +86 18686857197
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui
Xuesheng Liu, +86 18655193385, liuxuesheng@ahmu.edu.cn
The First Hospital of Jiaxing
Jiaxing, Zhejiang
Huadong Ni, +86 15068386387, huadongni@126.com
The First Hospital of Lanzhou University
Lanzhou, Gansu
Yatao Liu, +86 13919451548, doctorliuyt@163.com
Taizhou Hospital of Zhejiang Province
Linhai, Zhejiang
Lingyang Chen, +86 13757600208, chenly@enzemed.com
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi
Yunan Lin, +86 13768278751, 2277464077@qq.com
Qilu Hospital of Shandong University
Qingdao, Shandong
Dongliang Li
The Affiliated Hospital of Qingdao University
Qingdao, Shandong
Aijie Liu, +86 18661801683
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei
Huaqin Liu, +86 13582126106
First Hospital of Shanxi Medical University
Taiyuan, Shanxi
Jieping Lv, +86 13593131366
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang
Weifeng Yu, +86 13901961704, ywf808@yeah.net
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan
Jianjun Yang, +86 13357739238, jianjunyan91971@163.com
About this study
Official title: Effect of Renal Oxygenation-Guided Perioperative Management on Acute Kidney Injury After Elective Hepatectomy: A Multicenter, Randomized, Controlled, Parallel-Group Superiority Trial
Acute kidney injury (AKI) is a common complication after major liver surgery. This study will evaluate whether intraoperative management guided by renal regional oxygen saturation (RrSO₂), measured using near-infrared spectroscopy, can reduce postoperative acute kidney injury in adults undergoing elective hepatectomy. Approximately 1,200 participants at about 20 hospitals in China will be randomly assigned in a 1:1 ratio to RrSO₂-guided management or usual perioperative care.
All participants will undergo continuous bilateral renal RrSO₂ monitoring. In the intervention group, RrSO₂ values will be visible to the anesthesia team, and a decrease of 10% or more from baseline on either side will trigger a standardized assessment and stepwise management algorithm. In the control group, RrSO₂ data will be recorded but concealed from the clinical team and will not guide treatment.
The primary outcome is AKI within 7 days after surgery or before hospital discharge, whichever occurs first, based on Kidney Disease: Improving Global Outcomes serum creatinine criteria or initiation of renal replacement therapy.
Read the detailed description
ROGAR is an investigator-initiated, multicenter, prospective, randomized, parallel-group superiority trial enrolling approximately 1,200 adults aged 45 years or older undergoing elective open, laparoscopic, or robot-assisted hepatectomy under general anesthesia. Participants will be randomized 1:1 to renal oxygenation-guided management or usual perioperative care using a centralized allocation system stratified by study center.
All participants will undergo continuous bilateral renal regional oxygen saturation (RrSO₂) monitoring using near-infrared spectroscopy. Before randomization, kidney location and suitability for monitoring will be confirmed by ultrasound, and a baseline RrSO₂ value will be established for each side before anesthesia.
In the intervention group, RrSO₂ values will be visible to the anesthesia team. A decrease of 10% or more from the corresponding side-specific baseline will trigger confirmation of signal validity followed by a standardized stepwise management algorithm addressing clinically relevant determinants of oxygen delivery and perfusion. RrSO₂ and hemodynamic responses will be reassessed after each intervention. In the control group, RrSO₂ will be continuously recorded but concealed from the clinical team and will not guide perioperative management.
- Conditions
- Acute Kidney Injury, Hepatectomy
- Being tested
- INVOS 5100C regional oxygen saturation monitoring system, RrSO2-guided perioperative management, Usual perioperative management
- Keywords
- renal regional oxygen saturation; near-infrared spectroscopy; acute kidney injury; hepatectomy; perioperative management; kidney protection
- Medical subject headings
- Acute Kidney Injury
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
INVOS 5100C regional oxygen saturation monitoring systemDevice
Also called Near-infrared spectroscopy; bilateral renal RrSO2 monitoring
A near-infrared spectroscopy system will be used to continuously record bilateral renal regional oxygen saturation from before anesthesia induction until the end of the intraoperative monitoring period. The device is used in both study arms; display of the values differs by randomized allocation.
RrSO2-guided perioperative managementOther
When either renal RrSO2 decreases by at least 10% from its side-specific baseline, signal artifact and sensor displacement will first be excluded. The anesthesiologist will then assess and treat reversible causes using clinically appropriate measures that may include a small isotonic crystalloid bolus based on goal-directed volume assessment, titrated norepinephrine, dobutamine, treatment of hemodynamically significant bradycardia, optimization of ventilation and oxygenation, and red blood cell transfusion when predefined criteria are met. RrSO2 and hemodynamic responses will be reassessed after each action.
Usual perioperative managementOther
Perioperative anesthesia and hemodynamic management will follow current clinical practice and institutional standards. Renal RrSO2 values will remain hidden and will not be used for clinical decisions.
| Study group | Role | What they receive |
|---|---|---|
| Renal oxygenation-guided perioperative management | Experimental | Bilateral renal regional oxygen saturation will be continuously monitored and displayed to the designated anesthesiologist. A decrease of 10% or more from the corresponding side-specific baseline will trigger assessment of signal validity and a standardized, clinically individualized optimization process addressing volume status, perfusion pressure, cardiac output, heart rate, ventilation and oxygenation, and hemoglobin concentration. Responses after each intervention will be reassessed and recorded. Receives: Device: INVOS 5100C regional oxygen saturation monitoring system; Other: RrSO2-guided perioperative management |
| Usual perioperative management with blinded renal oxygenation monitoring | Active comparator | Bilateral renal regional oxygen saturation will be continuously recorded, but values and trends will be hidden from the anesthesia and surgical teams and will not be used to guide care. Participants will receive usual perioperative management according to current clinical practice and local standards. Receives: Device: INVOS 5100C regional oxygen saturation monitoring system; Other: Usual perioperative management |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of postoperative acute kidney injury
Proportion of participants who develop acute kidney injury (AKI), defined by any of the following: an increase in serum creatinine of ≥0.3 mg/dL (26.5 μmol/L) within 48 hours; an increase in serum creatinine to ≥1.5 times the preoperative baseline within 7 days; or initiation of new renal replacement therapy within 7 days. Urine-output criteria will not be used for the primary outcome.
Measured: From the end of surgery through postoperative day 7 or hospital discharge, whichever occurs first
Secondary outcomes (10)
Severity of postoperative AKI
Highest postoperative acute kidney injury (AKI) stage according to Kidney Disease: Improving Global Outcomes (KDIGO) criteria. Outcomes will include the highest KDIGO stage (no AKI, stage 1, stage 2, or stage 3) and the incidence of severe AKI, defined as KDIGO stage 2 or 3.
Measured: Through postoperative day 7 or hospital discharge, whichever occurs first
Postoperative peak serum creatinine
The highest serum creatinine concentration measured after surgery during the index hospitalization will be identified for each participant and reported in micromoles per liter (μmol/L).
Measured: From the end of surgery until hospital discharge, assessed up to 30 days after surgery.
Persistence and recovery of AKI
Among participants who develop AKI, the clinical course of AKI will be characterized according to prespecified definitions of transient AKI, persistent AKI, and kidney recovery.
Measured: From the end of surgery through postoperative day 7 or hospital discharge, whichever occurs first, assessed for up to 7 days.
New Initiation of Renal Replacement Therapy Within 7 Days After Surgery
The proportion of participants who newly initiate renal replacement therapy (RRT) for acute kidney injury from the end of surgery through postoperative Day 7 or hospital discharge, whichever occurs first. Renal replacement therapy includes any form of intermittent or continuous kidney replacement therapy initiated during the assessment period.
Measured: Through postoperative Day 7 or hospital discharge, whichever occurs first
Renal Replacement Therapy Dependence
The proportion of participants who are receiving renal replacement therapy through postoperative Day 30.
Measured: Through postoperative day 30
In-hospital clinical recovery outcomes
In-hospital outcomes will included ICU length of stay, postoperative hospital length of stay.
Measured: From the end of surgery to hospital discharge,assessed up to 30 days after surgery.
Postoperative morbidity and complication burden
Postoperative morbidity will be assessed by the Clavien-Dindo grade, and the Comprehensive Complication Index (CCI). The CCI will be calculated from all postoperative complications occurring within 30 days after surgery after assigning a Clavien-Dindo grade to each event and ranges from 0 (no complication) to 100 (death).
Measured: Through postoperative day 30
Health-related quality of life
Health-related quality of life will be assessed using the validated Chinese version of the EuroQol 5-Dimension 5-Level (EQ-5D-5L).
Measured: At baseline and postoperative day 30
Healthcare resource use and direct medical costs
Total direct medical costs incurred from randomization through postoperative Day 30 will be assessed in Chinese yuan (CNY).
Measured: From randomization through postoperative day 30
All-Cause Mortality Within 30 Days After Surgery
The outcome will be the proportion of participants who die from any cause within 30 days after surgery. The date of death will be recorded when available.
Measured: From the end of surgery through postoperative Day 30
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Sep 2026
- Study start20 Sep 2026 (estimated)
- Primary completion30 Nov 2027 (estimated)
- Study completion30 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Kidney InjuryStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Two-arm, 1:1, multicenter, parallel-group superiority trial comparing renal oxygenation-guided perioperative management with usual perioperative management.
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 1,200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Chinese PLA General Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Weidong Mi, Chinese PLA General Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07816640
- Sponsor's protocol ID
- PLAGH_ROGAR
- Acronym
- ROGAR
- Status last verified
- Sep 2026
- First submitted
- 2 Sep 2026
- Last updated
- 14 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Renal Oxygenation-Guided Perioperative Management on Acute Kidney Injury After Elective Hepatectomy: A Multicenter, Randomized, Controlled, Parallel-Group Superiority Trial
- ClinicalTrials.gov ID
- NCT07816640
- Acronym / sponsor ID
- ROGAR / PLAGH_ROGAR
- Conditions
- Acute Kidney Injury, Hepatectomy
- Keywords
- renal regional oxygen saturation; near-infrared spectroscopy; acute kidney injury; hepatectomy; perioperative management; kidney protection
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 1,200 participants (estimated)
- Lead sponsor
- Chinese PLA General HospitalUniversity, hospital or other
- Study start
- 20 Sep 2026 (estimated)
- Primary completion
- 30 Nov 2027 (estimated)
- Study completion
- 30 Dec 2027 (estimated)
- First posted
- 14 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Acute kidney injury (AKI) is a common complication after major liver surgery. This study will evaluate whether intraoperative management guided by renal regional oxygen saturation (RrSO₂), measured using near-infrared spectroscopy, can reduce postoperative acute kidney injury in adults undergoing elective hepatectomy. Approximately 1,200 participants at about 20 hospitals in China will be randomly assigned in a 1:1 ratio to RrSO₂-guided management or usual perioperative care.
All participants will undergo continuous bilateral renal RrSO₂ monitoring. In the intervention group, RrSO₂ values will be visible to the anesthesia team, and a decrease of 10% or more from baseline on either side will trigger a standardized assessment and stepwise management algorithm. In the control group, RrSO₂ data will be recorded but concealed from the clinical team and will not guide treatment.
The primary outcome is AKI within 7 days after surgery or before hospital discharge, whichever occurs first, based on Kidney Disease: Improving Global Outcomes serum creatinine criteria or initiation of renal replacement therapy.
Detailed description
ROGAR is an investigator-initiated, multicenter, prospective, randomized, parallel-group superiority trial enrolling approximately 1,200 adults aged 45 years or older undergoing elective open, laparoscopic, or robot-assisted hepatectomy under general anesthesia. Participants will be randomized 1:1 to renal oxygenation-guided management or usual perioperative care using a centralized allocation system stratified by study center.
All participants will undergo continuous bilateral renal regional oxygen saturation (RrSO₂) monitoring using near-infrared spectroscopy. Before randomization, kidney location and suitability for monitoring will be confirmed by ultrasound, and a baseline RrSO₂ value will be established for each side before anesthesia.
In the intervention group, RrSO₂ values will be visible to the anesthesia team. A decrease of 10% or more from the corresponding side-specific baseline will trigger confirmation of signal validity followed by a standardized stepwise management algorithm addressing clinically relevant determinants of oxygen delivery and perfusion. RrSO₂ and hemodynamic responses will be reassessed after each intervention. In the control group, RrSO₂ will be continuously recorded but concealed from the clinical team and will not guide perioperative management.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
- Model description
- Two-arm, 1:1, multicenter, parallel-group superiority trial comparing renal oxygenation-guided perioperative management with usual perioperative management.
| Arm | Type | Receives |
|---|---|---|
| Renal oxygenation-guided perioperative management | Experimental | Device: INVOS 5100C regional oxygen saturation monitoring system, Other: RrSO2-guided perioperative managementBilateral renal regional oxygen saturation will be continuously monitored and displayed to the designated anesthesiologist. A decrease of 10% or more from the corresponding side-specific baseline will trigger assessment of signal validity and a standardized, clinically individualized optimization process addressing volume status, perfusion pressure, cardiac output, heart rate, ventilation and oxygenation, and hemoglobin concentration. Responses after each intervention will be reassessed and recorded. |
| Usual perioperative management with blinded renal oxygenation monitoring | Active comparator | Device: INVOS 5100C regional oxygen saturation monitoring system, Other: Usual perioperative managementBilateral renal regional oxygen saturation will be continuously recorded, but values and trends will be hidden from the anesthesia and surgical teams and will not be used to guide care. Participants will receive usual perioperative management according to current clinical practice and local standards. |
Who may qualify
- Ages
- 45 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Age ≥45 years.
- Scheduled for elective open, laparoscopic, or robot-assisted hepatectomy.
- Planned general anesthesia with tracheal intubation and an expected surgical duration ≥2 hours.
- Stable preoperative serum creatinine available before randomization, with baseline estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m².
- Body mass index <30 kg/m² and bilateral renal cortex-to-skin distance ≤4 cm on ultrasound, allowing reliable bilateral renal NIRS monitoring and stable baseline RrSO₂ signals.
Key exclusion criteria (6 listed)
- Pre-existing or unstable renal dysfunction, including eGFR <60 mL/min/1.73 m², AKI before randomization, unstable or progressively increasing serum creatinine, end-stage kidney disease, chronic dialysis, previous kidney transplantation, or other significant renal disease that may interfere with postoperative AKI assessment.
- Concomitant surgery expected to directly affect renal function assessment, including nephrectomy, kidney transplantation, or renal artery or vein reconstruction.
- Emergency or rescue surgery, or inability to provide valid informed consent before surgery.
- Inability to obtain reliable bilateral renal RrSO₂ monitoring because of excessive tissue depth, positioning, skin lesions, scars, infection, hematoma, severe edema, jaundice, or other technical or anatomical factors despite appropriate sensor repositioning and troubleshooting.
- Severe systemic disease or high perioperative risk, including severe cardiac or pulmonary dysfunction, recent major cardiovascular or cerebrovascular events, severe anemia, or any condition judged by the investigator to make participation unsafe.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| INVOS 5100C regional oxygen saturation monitoring systemAlso: Near-infrared spectroscopy; bilateral renal RrSO2 monitoringA near-infrared spectroscopy system will be used to continuously record bilateral renal regional oxygen saturation from before anesthesia induction until the end of the intraoperative monitoring period. The device is used in both study arms; display of the values differs by randomized allocation. | Device | Renal oxygenation-guided perioperative management, Usual perioperative management with blinded renal oxygenation monitoring |
| RrSO2-guided perioperative managementWhen either renal RrSO2 decreases by at least 10% from its side-specific baseline, signal artifact and sensor displacement will first be excluded. The anesthesiologist will then assess and treat reversible causes using clinically appropriate measures that may include a small isotonic crystalloid bolus based on goal-directed volume assessment, titrated norepinephrine, dobutamine, treatment of hemodynamically significant bradycardia, optimization of ventilation and oxygenation, and red blood cell transfusion when predefined criteria are met. RrSO2 and hemodynamic responses will be reassessed after each action. | Other | Renal oxygenation-guided perioperative management |
| Usual perioperative managementPerioperative anesthesia and hemodynamic management will follow current clinical practice and institutional standards. Renal RrSO2 values will remain hidden and will not be used for clinical decisions. | Other | Usual perioperative management with blinded renal oxygenation monitoring |
Primary outcome
Incidence of postoperative acute kidney injury
Time frame: From the end of surgery through postoperative day 7 or hospital discharge, whichever occurs first
Proportion of participants who develop acute kidney injury (AKI), defined by any of the following: an increase in serum creatinine of ≥0.3 mg/dL (26.5 μmol/L) within 48 hours; an increase in serum creatinine to ≥1.5 times the preoperative baseline within 7 days; or initiation of new renal replacement therapy within 7 days. Urine-output criteria will not be used for the primary outcome.
10 secondary outcomes
Severity of postoperative AKI
Time frame: Through postoperative day 7 or hospital discharge, whichever occurs first
Postoperative peak serum creatinine
Time frame: From the end of surgery until hospital discharge, assessed up to 30 days after surgery.
Persistence and recovery of AKI
Time frame: From the end of surgery through postoperative day 7 or hospital discharge, whichever occurs first, assessed for up to 7 days.
New Initiation of Renal Replacement Therapy Within 7 Days After Surgery
Time frame: Through postoperative Day 7 or hospital discharge, whichever occurs first
Renal Replacement Therapy Dependence
Time frame: Through postoperative day 30
In-hospital clinical recovery outcomes
Time frame: From the end of surgery to hospital discharge,assessed up to 30 days after surgery.
Postoperative morbidity and complication burden
Time frame: Through postoperative day 30
Health-related quality of life
Time frame: At baseline and postoperative day 30
Healthcare resource use and direct medical costs
Time frame: From randomization through postoperative day 30
All-Cause Mortality Within 30 Days After Surgery
Time frame: From the end of surgery through postoperative Day 30
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Acute Kidney Injury
Not yet recruitingObservational study
Effect of Filter Lifespan in CRRT on New Infections in Critically Ill Patients With AKI
Acute Kidney Injury
Enrolling by invitationObservational study
ProNephro NGAL Test for Early Detection of Acute Kidney Injury in Adult ICU Patients (ALPACA)
Acute Kidney Injury
Enrolling by invitationObservational study
Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0
Acute Kidney Injury, Fluid Overload
Not yet recruiting
Hemodynamic Resuscitation Guided by Non-Invasive Mean Systemic Filling Pressure to Prevent Acute Kidney Injury in Septic Shock
Acute Kidney Injury Due to Sepsis
Recruiting
Processed Electroencephalography-guided General Anesthesia and Outcomes in Major Abdominal Surgery
Postoperative Acute Kidney Injury
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
20 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing INVOS 5100C regional oxygen saturation monitoring system, RrSO2-guided perioperative management and Usual perioperative management in people with Acute Kidney Injury and Hepatectomy, run by Chinese PLA General Hospital at 20 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 14 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 20 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Hao Li (15010665099, lihao301@126.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of postoperative acute kidney injury (time frame: From the end of surgery through postoperative day 7 or hospital discharge, whichever occurs first). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Sep 2026.